Fludarabine, Cyclophosphamide and Rituximab: An effective chemoimmunotherapy combination with high remission rates for chronic lymphocytic leukaemia

Irish Journal of Medical Science

Volumn 178, Issue 4, 2009, Pages 441-446

  Hayat, A ^a   McGuckin, S ^b   Conneally, E ^b   Brown, P V ^b   McCann, S R ^b   Lawler, M ^b   Quinn, F ^b   Delaney, E ^b   O'Rourke, P ^b   Liptrot, S ^b   O'Brien, D ^b   Vandenberghe, E ^b  

^a UNIVERSITY HOSPITAL GALWAY   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

CLL; FCR; Flow cytometry; MRD; PCR

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DRUG DERIVATIVE; FLUDARABINE; MONOCLONAL ANTIBODY; RITUXIMAB; VIDARABINE;

ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; HUMAN; MALE; MIDDLE AGED; NEUTROPENIA; REMISSION; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEUTROPENIA; REMISSION INDUCTION; TREATMENT OUTCOME; VIDARABINE;

EID: 79960924770     PISSN: 00211265     EISSN: 18634362     Source Type: Journal    
DOI: 10.1007/s11845-009-0358-9     Document Type: Article

References (23)

1. Keating M, Chiorazzi N, Messmer B et al (2003) Biology and treatment of chronic lymphocytic leukemia. American Society of Hematology Education Program, pp 153-175
2. Keating MJ, O'Brien S, Lerner S et al (1998) Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92(4):1165-1171 (Pubitemid 28369029)
3. Flinn IW, Byrd JC, Morrison C et al (2000) Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 96(1):71-75 (Pubitemid 30456452)
4. Catovsky D, Richards S, Hillmen P (2005) Early results from LRF CLL4: a UK multicenter randomized trial. Blood, vol 106 (Abstract 716)
5. Almasri NM, Duque RE, Iturraspe J et al (1992) Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 40(4):259-263. doi:10.1002/ajh.2830400404
6. Foran JM, Rohatiner AZ, Cunningham D et al (2000) European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18(2):317-324 (Pubitemid 30056420)
7. O'Brien SM, Kantarjian H, Thomas DA et al (2001) Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19(8):2165-2170 (Pubitemid 32366970)
8. Manshouri T, Do KA, Wang X et al (2003) Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101(7):2507-2513. doi:10.1182/blood-2002-06-1639 (Pubitemid 36857605)
9. Alas S, Bonavida B (2001) Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 61(13):5137-5144 (Pubitemid 32681546)
10. Keating MJ, Manshouri T, O'Brien S, et al (2002) A high proportion of molecular remission can be obtained with a Fludarabine, Cyclophosphamide, Rituximab combination (FCR) in chronic lymphocytic leukemia (CLL). Blood, vol 100, p 771a
11. Byrd JC, Waselenko JK, Maneatis TJ et al (1999) Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 17(3):791-795 (Pubitemid 29109307)
12. Keating MJ, O'Brien S, Kantarjian H et al (1993) Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 81(11):2878-2884 (Pubitemid 23162104)
13. Hayat A, O'Brien D, O'Rourke P et al (2006) CD38 expression level and pattern of expression remains a reliable and robust marker of progressive disease in chronic lymphocytic leukemia. Leuk Lymphoma 47(11):2371-2379. doi:10.1080/10428190600947727 (Pubitemid 44768432)
14. van Dongen JJ, Langerak AW, Bruggemann M et al (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17(12):2257-2317. doi:10.1038/sj.leu.2403202 (Pubitemid 38072572)
15. Rawstron AC, Kennedy B, Evans PA et al (2001) Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 98(1):29-35. doi:10.1182/blood.V98.1.29
16. Binet JL, Auquier A, Dighiero G et al (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis.Cancer 48(1):198-206. doi:10.1002/1097-0142(19810701)48: 1〈198::AID-CNCR2820480131〉3.0.CO;2-V (Pubitemid 11064396)
17. Clavio M, Miglino M, Spriano M et al (1998) First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease. Eur J Haematol 61(3):197-203 (Pubitemid 28439342)
18. Nguyen DT, Amess JA, Doughty H et al (1999) IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 62(2):76-82 (Pubitemid 29071265)
19. Di Gaetano N, Xiao Y, Erba E, Bassan R et al (2001) Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 114(4):800-809. doi:10.1046/j.1365-2141.2001.03014.x (Pubitemid 32953735)
20. Keating MJ, O'Brien S, Albitar M et al (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23(18):4079-4088. doi:10.1200/JCO.2005.12.051 (Pubitemid 46211313)
21. Winkler U, Jensen M, Manzke O et al (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94(7):2217-2224 (Pubitemid 29467667)
22. Thornton PD, Bellas C, Santon A et al (2005) Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis. Leuk Res 29(4):389-395. doi:10.1016/j.leukres.2004.09.008 (Pubitemid 40255812)
23. Voena C, Ladetto M, Astolfi M et al (1997) A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia 11(10):1793-1798. doi:10.1038/sj.leu.2400801 (Pubitemid 27458621)